| 连花清瘟胶囊对比奥司他韦治疗流行性感冒疗效和安全性的Meta分析 |
| 投稿时间：2020-12-16 修订日期：2021-04-26 点此下载全文 |
| 引用本文：熊明彪,曹辉,杨德钱.连花清瘟胶囊对比奥司他韦治疗流行性感冒疗效和安全性的Meta分析[J].药学实践杂志,2021,39(5):454~459 |
| 摘要点击次数: 2027 |
| 全文下载次数: 1509 |
|
| 基金项目:全国基层名老中医专家传承工作室支持[国中药办人教发（2015)25号]; 国家中医药管理局第六批名老中医药专家学术继承项目[国中医药人教发（2017)29号] |
|
| 中文摘要:目的 系统评价连花清瘟胶囊与奥司他韦治疗流行性感冒的有效性和安全性。方法 计算机检索PubMed、Embase、Cochrane图书馆、中国知网等数据库，收集连花清瘟胶囊或连花清瘟胶囊联合其他药物（试验组）对比磷酸奥司他韦或磷酸奥司他韦联合其他药物（对照组）治疗流行性感冒的随机对照试验(RCT)。提取有效率、病毒核酸转阴时间、退热时间和症状消退时间等结局指标，采用RevMan 5.3统计软件进行Meta分析。结果 共纳入14项研究，共计1459例患者。Meta分析结果显示，试验组患者的有效率、病毒核酸转阴时间和退热时间与对照组相比无显著性差异。在症状缓解方面，试验组患者的咳嗽消退和头痛消退效果优于对照组，差异有统计学意义。试验组患者的全身肌肉酸痛消退时间和咽痛消退时间与对照组无统计学差异。在安全性方面，试验组患者不良反应的发生率与对照组的差异无统计学意义。结论 连花清瘟胶囊治疗流行性感冒时的疗效和不良反应发生率与磷酸奥司他韦相近，在缓解咳嗽和头痛症状方面优于奥司他韦。 |
| 中文关键词:连花清瘟胶囊 奥司他韦 流行性感冒 安全性 Meta分析 |
| |
| Meta analysis if the efficacy and safety of Lianhua Qingwen capsule versus oseltamivir in the treatment of influenza |
|
|
| Abstract:Objective To evaluate the efficacy and safety of Llianhua Qingwen capsule versus oseltamivir in the treatment of influenza.Methods Data from PubMed, Cochrane Library, Embase, VIP, CNKI and CBM, RCTs about Lianhua Qingwen capsule or Lianhua Qingwen capsule combined with other drugs (trial group) versus oseltamivir (control group) in the influenza were collected. The outcome indicators such as the effective rate of extraction, the time for viral nucleic acid to become negative, the time for fever and the time for symptom resolution, etc., were used for Meta analysis with RevMan 5.3 statistical software.Results Totally 14 studies were included, involving 1459 patients. The Meta analysis results showed that there was no significant difference in the therapeutic effect, the time of virus turning negative and defervescence, and fever reduction time in the experimental group compared with the control group. In terms of symptom relief, the effect of cough and headache resolution in the experimental group was better than that in the control group, and the difference was statistically significant. There was no significant difference in the time to subside of general muscle soreness and pharyngeal pain in the test group and the control group. In terms of safety, there was no statistically significant difference in the incidence of adverse reactions between the experimental group and the control group.Conclusion Lianhua Qingwen capsule is similar to oseltamivir phosphate in curative effect and adverse reaction rate in the treatment of influenza, and is superior to oseltamivir in relieving cough and headache symptoms. |
| keywords:Lianhua Qingwen capsule oseltamivir influenza safety Meta analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
